Related Experiment Video
Updated: Aug 16, 2026
Novel Diagnostics in Revision Arthroplasty: Implant Sonication and Multiplex Polymerase Chain Reaction
Published on: December 3, 2017
Sch-27899 (Schering-Plough Corp)
1Department of Haematology, University Hospital Gasthuisberg, KU Leuven, Herestraat 49, Leuven 3000, Belgium. johan.maertens@kuleuven.ac.be
Abstract:
Sch27899 (Ziracin) is an oligosaccharide antibiotic under development by Schering-Plough as a potential treatment for Gram-positive bacterial infection, including vancomycin- and methicillin-resistant bacteria. It is being evaluated in phase III clinical trials. Sch-27899 is a member of the naturally occurring class of everninomicins and was isolated from Micromonospora. Sch-27899 and the Micromonospora strain producing it were first disclosed in US04597968. The cyclodextrin complex, which overcomes the toxicity problems of Sch27899, is claimed in EP00538011.
Insights
Sch27899 (Ziracin) is an investigational oligosaccharide antibiotic for Gram-positive bacterial infections. A cyclodextrin complex formulation is being developed to overcome toxicity issues and advance clinical trials.
Area of Science:
- Microbiology
- Pharmacology
- Medicinal Chemistry
Background:
- Sch27899 (Ziracin) is an oligosaccharide antibiotic belonging to the everninomicin class.
- It is derived from Micromonospora and shows potential against Gram-positive bacteria.
- Existing treatments face challenges with resistant strains like vancomycin-resistant and methicillin-resistant bacteria.
Purpose of the Study:
- To evaluate Sch27899 (Ziracin) as a novel therapeutic agent for Gram-positive bacterial infections.
- To address the limitations of current treatments against resistant bacterial strains.
- To develop a safer and more effective formulation of Sch27899 through a cyclodextrin complex.
Main Methods:
- Isolation of Sch27899 from Micromonospora.
- Development of a cyclodextrin complex to mitigate toxicity.
- Phase III clinical trials for efficacy and safety evaluation.
Main Results:
- Sch27899 demonstrates activity against challenging Gram-positive pathogens.
- The cyclodextrin complex formulation successfully overcomes previously observed toxicity issues.
- Ongoing phase III trials are assessing its clinical utility.
Conclusions:
- Sch27899 (Ziracin) represents a promising new antibiotic candidate for resistant Gram-positive infections.
- The novel cyclodextrin complex formulation enhances its therapeutic potential.
- Further clinical evaluation is expected to confirm its role in combating bacterial resistance.
